This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping

Wednesday, May 21, 2014

Submitted by


Source Name: Journal of Clinical Oncology


AG Sacher, LW Le, NB Leighl

This study evaluated over 200 RTCs of systemic therapy for NSCLC.  There has been a steady increase in the number of trials reporting outcomes for progression-free survival.  Over 50% of trials now report a positive outcome without meeting the primary endpoint of the trial.  Although the sample size of the trials is increasing, the magnitude of reported survival gain is decreasing (now 2.5 mos).

Add comment

Log in or register to post comments